Mesoblast Completes Treatment in Pivotal Phase 3 CLBP Trial; Top-Line Data Expected Mid-2027
MESO sits 35% above its 52-week low of $12.66 on elevated volume (2.1× avg).
Summary
Mesoblast completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, up from 300, with top-line results expected in mid-2027. The company projects over US$10 billion in potential peak revenue for the indication.
Key Events · Product Development and Regulatory · MESO
-
Phase 3 Treatment Completed
Mesoblast completed patient treatment in the MSB-DR004 pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain, with 350 patients randomized and treated, up from 300 previously reported.
-
Top-Line Data Timeline
Top-line results are expected in mid-CY2027 after the last treated patient completes 12 months of follow-up.
-
Commercial Opportunity
The company estimates potential peak year revenue of over US$10 billion for the CLBP indication even with single-digit market penetration.
-
Regulatory Pathway
Rexlemestrocel-L holds RMAT designation from the FDA, providing eligibility for priority review once a BLA is filed.
Analysis · MESO · Life Sciences
Mesoblast has completed patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain, expanding enrollment from 300 to 350 patients due to strong investigator demand. This milestone de-risks the trial's execution and sets a clear timeline for top-line results in mid-CY2027. The company estimates the indication could generate over US$10 billion in peak annual revenue even with single-digit market penetration, underscoring the commercial significance of this program. With RMAT designation and an FDA-agreed primary endpoint, a positive readout could support a BLA filing and priority review, positioning rexlemestrocel-L as a potential blockbuster.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 38.8% of the 970 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MESO was trading at $17.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $12.66 to $21.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.